I am a
Home I AM A Search Login

Papers of the Week

Papers: 15 Jun 2024 - 21 Jun 2024

2024 Jun 13

J Crohns Colitis


Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Program.


Danese S, Dignass A, Matsuoka K, Ferrante M, Long M, Redondo I, Moses R, Maier S, Hunter Gibble T, Morris N, Milch C, Abreu MT


Ulcerative colitis (UC), a chronic inflammatory bowel disease, may manifest with symptoms of increased stool frequency (SF), rectal bleeding (RB), bowel urgency (BU), abdominal pain (AP), and fatigue. Mirikizumab, an anti-IL-23p19 antibody, demonstrated efficacy and safety in patients with moderately to severely active UC in the LUCENT Phase 3 trials. We evaluated mirikizumab’s efficacy in achieving symptom control and time to symptom improvement during induction, maintenance of sustained symptom control, “comprehensive symptom control”, defined according to a combination of individual patient-reported outcomes, and prognostic baseline indicators of early symptomatic remission at week 4.